Timing and trajectory of pain and functional outcomes after basivertebral nerve ablation: a prospective cohort study Authors: Charles A Odonkor, Oghenewoma Oghenesume, Sera Yoo, Sergio Mosquera Limas, Jacky Yeung, Patrick Doherty, Sumeet Kadian, Jared Rosenberg, Sudhir K Kadian, Peter G Whang Published: 2025 ABSTRACT AbstractBackgroundBasivertebral nerve ablation (BVNA) is an FDA-cleared treatment for vertebrogenic low back pain. However, limited data exist detailing the specific timing and durability of patient-reported relief.ObjectiveTo characterize the weekly temporal trajectory of patient-reported ≥50 % pain relief and evaluate the predictive value for short-term and sustained response.MethodsThis prospective observational cohort study included 86 consecutive patients with MRI-confirmed Modic Type 1 or 2 changes treated with intraosseous BVNA between April 2024 and April 2025 at an academic center. Patients reported weekly pain relief for 8 weeks, then again at 12 and 24 weeks. Primary outcomes were time to first ≥50 % relief and the positive and negative likelihood ratios (LR+, LR−) of early improvement for predicting response. Secondary outcomes included changes in Oswestry Disability Index (ODI), Numeric Rating Scale (NRS), and adjunctive spine interventions.ResultsPain reduction was rapid and durable: By Week 1, 34 % of patients achieved ≥50 % relief, increasing to 76 % by Week 3 and 91 % by Week 6. These improvements plateaued through Week 12 and persisted at 24 weeks. Median time to first ≥50 % relief was 3 weeks. Early responders (Week 3) were 6.6 times more likely to maintain relief at Week 12 (LR+ = 6.56, 95 % CI 2.50–17.0); predictive utility peaked at Weeks 4–6 (LR+ 7.1–9.0; LR− ≤ 0.13). Mean ODI improved from 66.5 ± 13.5 to 32.3 ± 15.8 and NRS from 8.3 ± 1.5 to 3.0 ± 2.6 (p < 0.0001 for both). Nearly 90 % achieved ≥15-point ODI and ≥2-point NRS improvement; 21 % were pain-free by Week 12. Use of adjunctive spine injections declined from 86 % pre-procedure to 22 % post-procedure (p < 0.0001).ConclusionThis is the first study to prospectively characterize the weekly time course of response following BVNA and demonstrates early, substantial, and durable improvements in pain and function. Most patients experienced meaningful relief within 3–6 weeks, and early response was sustained through 24 weeks. These findings support BVNA as a robust real-world intervention for vertebrogenic pain and highlight the prognostic value of early pain trajectory monitoring in predicting sustained outcomes.Keywords: Basivertebral nerve ablation, Vertebrogenic low back pain, Responder phenotypes, Pain relief trajectory Introduction Chronic axial low back pain (CLBP) remains a leading cause of global disability, with significant implications for patient function, quality of life, and healthcare utilization [1]. For a substantial subset of patients, symptoms are driven by vertebrogenic pain originating from damage and inflammation of the vertebral endplates, often radiographically characterized by Modic Type 1 or 2 changes [2,3]. The basivertebral nerve (BVN), which innervates the vertebral endplates, has been identified as a key nociceptive contributor in this population [4,5]. Intraosseous basivertebral nerve ablation (BVNA) has emerged as an effective, FDA-approved treatment for vertebrogenic CLBP [[6], [7], [8], [9]]. Early randomized controlled trials demonstrated clinically meaningful improvements in pain and function compared to sham procedures, with durability extending through 2- and 5-year follow-up in treatment arms [10,11]. These findings were corroborated by subsequent multicenter prospective studies and pooled data analyses [[12], [13], [14], [15]]. The technique has been shown to reduce healthcare utilization and costs over time, supporting its broader adoption in clinical practice [[6], [7], [8], [9],16]. Despite the growing body of evidence supporting the safety and effectiveness of BVNA, the specific weekly temporal trajectory of symptom relief following the procedure remains poorly defined. While prior trials have captured outcomes at pre-specified time points (for example, 3 months, 6 months, 1 year), granular week-by-week data on early response patterns are lacking. Understanding the timeline of pain improvement is critical for setting patient expectations, guiding post-procedural follow-up, and identifying early treatment failures. Furthermore, early identification of “responder phenotypes"—patients who experience meaningful relief within the first few weeks—could enable clinicians to tailor post-procedural care and inform shared decision-making. Prior studies have examined the association between baseline clinical characteristics and overall treatment success; however, temporal dynamics of pain relief following BVNA—including the time to onset of meaningful response—have not been systematically evaluated [17,18]. The current study addresses this knowledge gap through a prospective, observational cohort design. We aim to (1) characterize the temporal pattern of ≥50 % pain relief following BVNA over a 24-week period, (2) assess the predictive value of early response for sustained outcomes, and (3) describe distinct responder profiles based on timing and magnitude of pain relief. In doing so, we seek to provide practical, real-world data that complement existing long-term trial results and enhance the clinical utility of BVNA in routine care. Methods This prospective, observational cohort study was designed to evaluate temporal trends and predictors of clinical response in adult patients undergoing BVNA for chronic low back pain. The study was conducted at a single major academic medical institution. All procedures and assessments adhered to the principles outlined in the Declaration of Helsinki. The protocol was approved by the Institutional Review Board at Yale University School of Medicine (IRB #2000040858). No component of the BVNA procedures, follow-up assessments, or ancillary care was supported by industry sponsorship, and all costs were borne through routine clinical care or institutional research funds. Study design and oversight Eligible patients were enrolled between April 19, 2024, and April 19, 2025. Participants were followed from baseline through six months post-procedure, with data collected through a combination of in-person visits and remote (telephone or video-based) check-ins. Patient-reported outcomes were assessed weekly during the first 8 weeks, and then again at 3 and 6 months following the procedure. Standardized instruments used included the Oswestry Disability Index (ODI), Numeric Rating Scale (NRS) for pain and patient perceived percent pain relief. The study did not involve randomization, blinding, or treatment group assignments. All patients received the same clinical intervention based on standard-of-care indications. The primary aim was to observe real-world outcomes and determine how quickly pain relief emerges after BVNA and sustainability of response with time. Participants, inclusion and exclusion criteria Inclusion criteria required that participants: 1.Exhibited clinical features suggestive of vertebrogenic pain based on history and physical examination, as determined by the enrolling investigators; 2. Demonstrated Type 1 and/or Type 2 Modic changes on lumbar spine magnetic resonance imaging (MRI) at all the vertebral levels targeted for BVNA; 3. Had persistent pain for ≥6 months despite guideline-directed conservative management, including medications, physical therapy, and/or spinal injections; 4. Provided written consent to participate and agreed to complete all scheduled assessments; 5. Underwent BVNA at clinically indicated vertebral levels with positive demonstrated Type 1 and/or Type 2 Modic changes. Diagnosis of vertebrogenic pain was supported by both imaging and characteristic clinical presentation. Symptoms typically included midline or paramedian low back pain without leg-dominant radicular features, worsening with forward flexion, sitting, or standing, and relief in the recumbent position. On physical examination, patients demonstrated midline tenderness over the affected vertebral segments, preserved neurological function, and absence of dermatomal sensory or motor deficits. These findings are consistent with previously published diagnostic frameworks describing pain mediated by basivertebral nerve pathology. Patients were excluded if they met any of the following criteria: 1. Prior spinal cord stimulation (SCS) or dorsal root ganglion (DRG) stimulation within 6 months preceding enrollment; 2. Active or uncontrolled psychiatric illness, opioid dependence, or substance use disorder that could confound outcome assessment; 3. Cognitive impairment, language barrier, or other condition preventing accurate self-reporting of symptoms or comprehension of study procedures; 4. Structural spinal deformities, infection, or neoplastic lesions precluding BVNA; 5. Ongoing litigation or compensation-related claims for back pain. Basivertebral nerve ablation procedure All participants underwent fluoroscopically guided BVNA using the Intracept® System (Boston Scientific, MA, USA). Procedures were performed by board-certified, fellowship-trained interventional pain physicians with specialized training in the technique. Patients were treated at only MRI confirmed FDA-approved levels (L3–S1), as well as qualifying off-label levels (L1, L2, S2) with Modic type 1 and/or 2 changes. Any levels without MRI confirmed Modic changes were excluded and not targeted for ablation. Treatments were performed under general anesthesia in an outpatient setting. With the patient in a prone position, sterile preparation and draping were followed by adjustment of the fluoroscopic C-arm to square the superior endplate of the target vertebra in the anteroposterior (AP) view. The C-arm was then rotated approximately 20–35° to identify the superolateral pedicle and the skin entry point. A Ferguson view was obtained for sacral S1 or S2 access as indicated. After local infiltration with 1 % lidocaine using a 25-gauge needle, a 22-gauge spinal needle was used to anesthetize the pedicle track. An 8-gauge introducer cannula was advanced through the soft tissues into the posterior vertebral body under biplanar (AP and lateral) fluoroscopic guidance. A transpedicular or parapedicular approach was used in accordance with the manufacturer's specifications and published technique standards. Once bony access was confirmed, the curved cannula assembly and nitinol J-stylet were inserted. The stylet-cannula assembly was gradually advanced under continuous fluoroscopy until the tip of the stylet reached the target ablation zone—between 30–50 % of the vertebral body depth in the lateral view and just crossing midline in the AP view. The stylet was removed, and a bipolar radiofrequency (RF) probe was inserted. After verifying placement, thermal ablation was delivered at 75 °C for 7 min or at 85 °C for 15 min at lumbar levels, and at 85 °C for 15 min S1 or S2 levels due to anatomical variability. The duration of ablation was performed in accordance with the current manufacturer guidelines. Two parameter sets are available within the latest generation of the Intracept® RF generator: 1. Targeted Ablation Parameters: 75 °C for 7 min (0.5 °C/s temperature ramp), generating an approximate 5 mm radial lesion; 2. Expanded Ablation Parameters: 85 °C for 15 min (1.0 °C/s temperature ramp), generating an approximate 6 mm radial lesion. Selection of ablation duration was determined at the discretion of the treating physicians, based on intraoperative fluoroscopic assessment of probe position relative to the basivertebral foramen. This approach was consistent with the study protocol. A 7-min ablation was used when probe alignment was within approximately 5 mm of the intended target; a 15-min ablation was applied when slightly greater distance or less ideal targeting required a larger lesion radius to ensure comprehensive nerve capture. These dual ablation options were introduced following progressive refinements to the Intracept® system across three design generations, which have improved targeting accuracy and procedural efficiency. The 7-min “targeted” ablation reflects the current manufacturer standard for on-target lesions and is supported by recently published data demonstrating comparable outcomes using this parameter set (Fogel 2024; McCormick 2025). While this study was not powered to detect outcome differences by ablation duration, exploratory comparisons revealed no significant differences in pain or functional improvement between 7- and 15-min lesions. Accordingly, both durations were included in the final analysis. After all levels were treated, the RF probe and cannula were removed, and the skin was closed with adhesive or a simple dressing. Post-procedure care and usual care interventions Following BVNA, patients were discharged the same day and encouraged to gradually resume activity as tolerated. Usual post-procedure care was individualized based on shared decision-making between the patient and treating clinicians. Additional pain management interventions, if required, were recorded, and categorized for analysis. These included: 1. Diagnostic or therapeutic spinal injections, such as epidural steroid, facet joint, medial branch, sacroiliac joint, or nerve root injections; 2. Radiofrequency ablation (RFA) targeting lumbosacral medial branches; 3. Peripheral nerve stimulation (PNS) targeting lumbosacral or peripheral pain generators. The frequency and type of post-BVNA procedures within the 6-month period before and after BVNA were compared to evaluate changes in utilization of adjunctive interventions. Data collection and outcomes Demographic and baseline clinical variables (age, sex, BMI, pain duration, and Modic type) were abstracted from the electronic medical record. Pain intensity was assessed using the Numeric Rating Scale (NRS, 0–10) and functional disability was measured using the Oswestry Disability Index (ODI) at baseline and weekly through 12 weeks, and at 24 weeks. In addition, the Patient Global Impression of Change (PGIC) was recorded at each follow-up. Patients reported percent pain relief at each visit to assess trajectory and cumulative response. All outcomes were analyzed both continuously and dichotomously (e.g., ≥50 % pain relief; ≥15- or ≥30-point ODI improvement thresholds). The primary outcome was the proportion of patients achieving ≥50 % pain relief at 12 and 24 weeks, based on NRS ratings. Secondary outcomes included earlier response milestones at weeks 2, 4 and 6 weeks. Tertiary analyses included: likelihood ratio of sustained response at 24-weeks given early response (3–6 weeks) and short-term response (12 weeks), evaluation of “high responders” (≥80 % pain relief) and changes in proportions meeting clinically meaningful thresholds for ODI (≥15-point and ≥30-point change) and NRS (≥2 point change). Statistical analysis Descriptive statistics summarized demographic and baseline characteristics. Continuous variables were reported as mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables were presented as counts and percentages. Changes from baseline to follow-up were evaluated using paired t-tests or Wilcoxon signed-rank tests for continuous data, and chi-square or Fisher's exact tests for categorical data. Kaplan-Meier survival analyses were conducted to examine time to first clinically meaningful pain relief. Likelihood ratios (positive and negative) were calculated from two-by-two contingency tables to evaluate the predictive utility of early response for subsequent outcomes. A p-value <0.05 was considered statistically significant. Exploratory subgroup analyses were performed to evaluate whether outcomes differed according to ablation duration (7-min vs. 15-min lesions). Given that ablation time selection reflected real-world procedural discretion rather than random assignment, these comparisons were descriptive in nature. Effect sizes were calculated to estimate the magnitude of any observed differences. No statistically significant differences were found between ablation durations, and both were therefore pooled for the primary analyses. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC) and verified with cross-validation in R (version 4.3.2). Minimizing bias Several strategies were employed to minimize bias in this prospective observational study. Selection bias was reduced by enrolling consecutive patients who met pre-specified clinical criteria for BVNA, independent of study participation. To mitigate reporting any recall bias, patient-reported pain relief was collected weekly using structured surveys, limiting retrospective inaccuracies. Observer bias was minimized by standardizing follow-up intervals and ensuring that clinical assessments were conducted using validated instruments (NRS, ODI). Although the absence of a control arm introduces potential confounding and limits causal inference, the study's real-world design enhances generalizability. Furthermore, missing data were minimal, and all patients included in the final analysis completed 12-week follow-up, reducing attrition bias. Results Participant characteristics A total of 86 patients who underwent BVNA were included in the final analysis (Table 1). Fig. 1 displays the enrollment and study completion flow. Of the 100 patients approached for participation, 90 enrolled; 2 proceeded to spine fusion prior to treatment and were therefore excluded. 88 subjects initiated the study, 2 were excluded due to hospitalization (n = 1) or pursuing alternative regenerative treatment (n = 1). Ultimately, 86 patients completed all required follow-up assessments and were included in the final analytic cohort (Fig. 1). The final sample included a balanced distribution across sex, age, and BMI categories. Most participants exhibited Modic type 1 or 2 changes at treated vertebral levels, consistent with vertebrogenic endplate-driven pathology (Table 1). All patients underwent BVNA at MRI-confirmed spinal levels with Modic type 1/and 2 changes, and follow-up was completed through 24 weeks post-procedure. As shown in Table 1 and Fig. 2, most patients were female (60.5 %) and between the ages of 50–79 years (64.9 %). The median age was 65 years (IQR: 45–75). Most patients fell into overweight or obese BMI categories, with 50 % meeting criteria for Obesity Class I or higher (median BMI: 32.5, IQR: 27.5–37.5). The majority (53.5 %) reported a chronic pain duration of 5–10 years (median: 7.5 years, IQR: 5–13), and 84 % had received BVNA across multiple vertebral levels, most commonly L3–S1 (42 %) and L4–S1 (31 %). For off-label treatments, two participants received BVNA treatments from L2-L5 (4-levels), four at L2-S1 (5-levels), and two at L5-S2 (3-levels). Among treated levels, 46.5 % of patients underwent 15-min ablations at all targeted vertebrae, 30.2 % received a combination of 7- and 15-min ablations across different levels, and 23.3 % underwent exclusively 7-min ablations. Table 1Baseline Characteristics of Study Participants Undergoing Basivertebral Nerve Ablation. This table presents demographic and clinical characteristics of patients enrolled in the study, including age distribution, sex, BMI categories, baseline pain scores, chronic pain duration, and vertebral levels treated with BVNA. Percentages are calculated based on the total sample size (N = 86).Table 1Demographic dataVariableNumber (%)Age (years)<402 (2.33)40–4913 (15.12)50–5920 (23.26)60–6914 (16.28)70–7921 (24.42)>8016 (18.60)SexFemale52 (60.47)Male34 (39.53)BMI (kg/m2)Normal weight (18.5–24.9)16 (18.60)Overweight (25.0–29.9)27 (31.40)Obesity Class I (30.0–34.9)28 (32.56)Obesity Class II (35.0–39.9)8 (9.30)Obesity Class III (40.0 and above)7 (8.14)Baseline Oswestry Disability Index (ODI)Minimal (0–20 %)0 (0)Moderate (21–40 %)5 (5.80)Severe (41–60 %)29 (33.70)Crippled (61–80 %)43 (50.00)Bed-bound (>80 %)9 (10.5 %)Baseline Pain Scores/NRS6-841 (47.67)9-1045 (52.33)Chronic Pain Duration (Years)<516 (18.60)5–1046 (53.49)11–1519 (22.09)>155 (5.81)BVNA Ablation Time15 min for all levels40 (46.5)Both 7 min & 15 min26 (30.2)7 min for all levels20 (23.2)BVNA LevelsL2-L52 (2.33)L2-S14 (4.65)L3-L511 (12.79)L3-S136 (41.86)L4-S127 (31.4)L5-S14 (4.65)L5-S22 (2.33) Baseline Characteristics of Study Participants Undergoing Basivertebral Nerve Ablation. This table presents demographic and clinical characteristics of patients enrolled in the study, including age distribution, sex, BMI categories, baseline pain scores, chronic pain duration, and vertebral levels treated with BVNA. Percentages are calculated based on the total sample size (N = 86). Flow diagram of patient recruitment and participation. Of the 100 patients approached, 10 declined to participate. A total of 90 patients were enrolled, of whom 2 proceeded to spine fusion before baseline and were excluded. Among the 88 patients who started the study, 2 were excluded due to hospitalization or seeking alternative regenerative treatments. Ultimately, 86 patients completed the full study protocol. Demographic dashboard of patients undergoing basivertebral nerve ablation (BVNA). Visual summary of cohort characteristics including age, sex, BMI, chronic pain duration, and BVNA levels. Median and interquartile ranges (IQRs) are shown for continuous variables. Cumulative and time specific responder analysis Pain reduction was substantial and sustained through 24 weeks following BVNA (Fig. 3). At 12 weeks, 74 % of patients achieved ≥50 % reduction in pain scores, and this proportion remained stable at 73 % at 24 weeks, demonstrating durable efficacy. The largest subgroup of patients experienced a 75–99 % reduction in pain (26 % at 12 weeks; 27 % at 24 weeks), while complete (100 %) pain resolution occurred in approximately one-fifth of the cohort at both time points. Overall, distributions of pain improvement were comparable between 12- and 24-week assessments, indicating consistent analgesic benefit over time. As illustrated in Fig. 4 (top row), cumulative responder rates (derived from a dichotomous variable indicating whether patients achieved ≥50 % pain relief at any follow-up time point [yes vs. no]) revealed a rapid accumulation of responders within the first few weeks: 34 % by Week 1, 76 % by Week 3, and 91 % by Week 6. By Week 12, a cumulative 91.2 % of patients had reported ≥50 % pain relief. This cumulative representation reflects the total proportion of patients who achieved clinically meaningful relief over time, rather than a single time-point estimate. When response was assessed using continuous percent improvement from baseline, the proportion achieving ≥50 % pain reduction ranged from 74 % to 83 % across specific time points (Fig. 4, middle row). This aligns with previously published meta-analyses and real-world cohorts reporting 64–72 % responder rates at 6–24 months after BVNA, and also with higher-response early-phase trials (De Vivo et al., 2021: 96.5 %, Fishchenko et al., 2021: 84.2 %). “Cumulative analyses capture both early and short-term responders, whereas continuous percent-improvement analyses (Fig. 4, middle row) illustrate pain reduction at specific time points. These findings highlight that observed responder rates are dependent on the analytic approach and timing of assessment, with cumulative metrics capturing both early and sustained benefit. Distribution of Percent Pain Reduction Following BVNA at 12 and 24 Weeks. Bar graph illustrating the proportion of patients achieving varying levels of percent pain reduction from baseline at 12 and 24 weeks following basivertebral nerve ablation (BVNA). Trajectories and Timing of Pain Relief Following Basivertebral Nerve Ablation Top row: shows the cumulative proportion of responders derived from the dichotomous variable indicating whether patients achieved ≥50 % pain relief at each follow-up time point (yes vs. no) from week 1 through week 24. The x-axis is ordered chronologically. Middle row: illustrates the specific proportions of pain relief over time, based on a continuous variable representing percent improvement from baseline NRS, with proportions reflecting patients meeting the ≥50 % pain-relief threshold. Bottom row: displays a Kaplan–Meier survival curve depicting the time to first report of ≥50 % pain relief, with censoring indicated where applicable. Patients were followed for up to 24 weeks post-BVNA. By 4–6 weeks after BVNA, 80–90 % of patients had reported at least 50 % pain relief. Timing of pain relief and predictive utility of early pain relief The Kaplan–Meier survival curve (Fig. 4, bottom row) depicts the time to first report of ≥50 % pain relief. Most patients reported clinically meaningful relief by 4–6 weeks post-BVNA, with the curve plateauing by Week 8, indicating that the majority of improvement occurred early and was durable through 24 weeks. Censoring was minimal, supporting the robustness of observed outcomes. The relationship between early pain relief (1–6 weeks) and short-term (Week 12) outcomes was explored using two-by-two contingency tables (Table 2) and positive likelihood ratios (LR+) with 95 % confidence intervals (Fig. 5, top row). By Week 3, patients achieving ≥50 % relief had a LR+ of 6.56 (95 % CI: 2.50–17.00), indicating strong predictive value for sustained response at Week 12. This predictive utility peaked between Weeks 4–6, with LR+ values ranging from 7.08 to 9.00. Negative likelihood ratios (LR−) during this window were low (≤0.13), supporting the potential utility of early nonresponse as a signal for reconsideration of treatment trajectory. Positive predictive value (PPV) was consistently high, reaching 98–99 % from Week 3 onward, while negative predictive value (NPV) improved gradually over time but remained modest until Week 6 (Fig. 5, top row). Early nonresponse was also evaluated as a potential predictor of later outcomes (Table 3). Lack of ≥50 % pain relief at Week 3 was associated with a negative likelihood ratio (LR−) = 0.00 for achieving response at 24 weeks, while nonresponse at Week 12 was associated with LR− = 0.54. These findings suggest that early (by 3–4 weeks) and short-term (by 12 weeks) nonresponse may serve as clinically useful indicators for reconsidering treatment trajectory. Table 2Week-by-Week Predictive Value of Early Pain Relief Compared to 12-Week Response This table summarizes two-by-two classification results comparing pain relief reported at Weeks 1–8 to the gold-standard 12-week outcome of ≥50 % pain relief. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive and negative likelihood ratios (LR+, LR−) are provided for each weekly timepoint. These values help estimate the prognostic utility of early response following BVNA.Table 2Week reporting ≥50 % pain reliefWeek 12 as the reference gold standard for expected outcomesTPFPFNTNSensitivitySpecificityPPVNPVLR+LR-12934950.370.630.910.090.991.0123913970.500.880.980.154.000.5736411470.820.880.980.336.560.214691970.880.880.990.447.080.135741470.950.880.990.647.590.066771081.000.890.990.889.000.007761180.990.891.000.808.880.018781071.000.880.991.008.000.00 Week-by-Week Predictive Value of Early Pain Relief Compared to 12-Week Response This table summarizes two-by-two classification results comparing pain relief reported at Weeks 1–8 to the gold-standard 12-week outcome of ≥50 % pain relief. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive and negative likelihood ratios (LR+, LR−) are provided for each weekly timepoint. These values help estimate the prognostic utility of early response following BVNA. Likelihood ratio of response and magnitude of patient-reported pain relief at different time points post-BVNA Top row: Positive likelihood ratios (LR+) with 95 % confidence intervals for ≥50 % pain relief by follow-up week using Week 12 as the reference standard. Grey bars denote LR + estimates, with black lines representing the 95 % confidence interval. Predictive utility zones and thresholds (e.g., LR+ > 5) are annotated. Individuals reporting at least 50 % pain relief between 3 and 6 weeks post-BVNA have high likelihood of response by week 12. Bottom row: Patient reported relief at 2, 6, and 12 weeks following basivertebral nerve ablation. Bar plot illustrates the proportion of patients reporting varying levels of pain relief (% bins) at 2, 6, and 12 weeks. Relief is grouped by decile bins (e.g., 0 %, 1–10 %, …, 91–100 %). The distribution shifts toward higher relief thresholds over time, with the greatest concentration of patients reporting 91–100 % pain relief by Week 12. Table 3Predictive Value of Early and Short-Term Nonresponse for 24-Week Outcomes Following BVNA. This table displays contingency table–derived metrics evaluating early (3-week) and short-term (12-week) nonresponse as predictors of persistent nonresponse at 24 weeks. Early nonresponse at 3 weeks demonstrated a negative likelihood ratio (LR−) of 0.00, whereas short-term nonresponse at 12 weeks yielded an LR− of 0.54, suggesting that absence of ≥50 % pain relief by these time points may serve as a clinically meaningful indicator for reassessing treatment trajectory.Table 3PredictorTPFPFNTNSensitivitySpecificityNegative LR (LR−)No response at 3 weeks1560651.0000.9150.00No response at 12 weeks718700.4670.9860.54 Predictive Value of Early and Short-Term Nonresponse for 24-Week Outcomes Following BVNA. This table displays contingency table–derived metrics evaluating early (3-week) and short-term (12-week) nonresponse as predictors of persistent nonresponse at 24 weeks. Early nonresponse at 3 weeks demonstrated a negative likelihood ratio (LR−) of 0.00, whereas short-term nonresponse at 12 weeks yielded an LR− of 0.54, suggesting that absence of ≥50 % pain relief by these time points may serve as a clinically meaningful indicator for reassessing treatment trajectory. Magnitude of short-term patient perceived improvement Magnitude of short-term relief (≤3 months) was computed by evaluating patient reported percent pain relief in deciles. The distribution of percent pain relief at Weeks 2, 6, and 12 is shown in Fig. 5, bottom row. Over time, a rightward shift in the distribution curve was observed, with an increasing proportion of patients reporting relief levels ≥80 % and ≥90 %. By Week 12, most patients fell into the highest decile (91–100 %) with 21 % of respondents noting they were pain-free (100 % relief). These findings complement the responder analysis by illustrating not only the proportion achieving meaningful relief but also the depth and perceived magnitude of that relief, underscoring both internal consistency and the strength of the overall analgesic effect. Functional and pain outcomes As shown in Table 4, both disability and pain scores improved substantially following BVNA and were maintained through 24 weeks. Mean ODI decreased from 66.5 ± 13.5 at baseline to 32.3 ± 15.8 at 12 weeks and remained stable at 32.1 ± 15.8 at 24 weeks (p < 0.0001). Similarly, mean NRS scores improved from 8.3 ± 1.5 to 3.0 ± 2.6 at both follow-up time points (p < 0.0001). Approximately 70–90 % reported ≥15–30-point improvement ODI and 90 % noted ≥2 reduction in NRS, comparable with prior reports [7,[11], [12], [13], [14],19]. Median ODI and NRS values followed a comparable trend, indicating a clinically meaningful and durable reduction in pain intensity and disability. Table 4Comparison of ODI and NRS Scores Before and After Basivertebral Nerve Ablation (12 weeks vs. 24 weeks). This table shows the Mean and median Oswestry Disability Index (ODI) and Numeric Rating Scale (NRS) scores at baseline, 12 weeks, and 24 weeks post-BVNA, with corresponding p values for within-subject improvement compared to baseline.Table 4VariableMeasureBaseline12 weeks (N = 86), p-value24 weeks (N = 86), p-valueODIMean ± SD66.5 ± 13.532.3 ± 15.8, p < 0.000132.1 ± 15.8, p < 0.0001Median (Min, Max)68.0 (36.0, 96.0)30.0 (10.0, 84.0)30.0 (10.0, 84.0)NRSMean ± SD8.3 ± 1.53.0 ± 2.6, p < 0.00013.0 ± 2.6, p < 0.0001Median (Min, Max)9.0 (3.0, 10.0)2.0 (0.0, 10.0)2.0 (0.0, 10.0) Comparison of ODI and NRS Scores Before and After Basivertebral Nerve Ablation (12 weeks vs. 24 weeks). This table shows the Mean and median Oswestry Disability Index (ODI) and Numeric Rating Scale (NRS) scores at baseline, 12 weeks, and 24 weeks post-BVNA, with corresponding p values for within-subject improvement compared to baseline. Proportion achieving clinically meaningful improvement As summarized in Table 5, the majority of patients achieved significant functional and pain improvement by 12 weeks, with results sustained at 24 weeks. Whereas 89.5–90.7 % of patients demonstrated an ODI reduction ≥15 points, approximately 70 % achieved an ODI reduction ≥30 points at 12 and 24 weeks. Notably, 82.6 % reported a ≥50 % decrease in pain intensity based on NRS, and 91 % experienced a ≥ 2-point NRS improvement at both time points. Consistent with these findings, 91.9 % of patients reported a PGIC ≥6, reflecting substantial perceived overall improvement and satisfaction with treatment. Collectively, the results demonstrate that BVNA yielded statistically and clinically significant improvements in pain, function, and patient-perceived benefit, with outcomes stable through 24 weeks of follow-up. Table 5Summary of Clinical Outcomes at 12 and 24 Weeks Following Basivertebral Nerve Ablation. This table illustrates the proportion of patients achieving predefined thresholds for improvement in ODI, NRS, and Patient Global Impression of Change (PGIC), reflecting pain relief, functional recovery, and perceived benefit over time.Table 5Outcome Variable12 weeks (N = 86)24 weeks (N = 86)ODI score reduction (Mean ± SD)34.2 ± 16.234.4 ± 16.0ODI ≥15-point reduction, n (%)77 (89.5 %)78 (90.7 %)ODI ≥30-point reduction, n (%)60 (69.8 %)59 (68.6 %)Pain Relief ≥50 % decrease, n (%)71 (82.6 %)71 (82.6 %)NRS score reduction (Mean ± SD)5.3 ± 2.95.3 ± 2.8NRS ≥ 2-point reduction, n (%)77 (89.5 %)78 (90.7 %)PGIC ≥6, n (%)79 (91.9 %)79 (91.9 %) Summary of Clinical Outcomes at 12 and 24 Weeks Following Basivertebral Nerve Ablation. This table illustrates the proportion of patients achieving predefined thresholds for improvement in ODI, NRS, and Patient Global Impression of Change (PGIC), reflecting pain relief, functional recovery, and perceived benefit over time. Responder phenotypes Based on timing and magnitude of relief, patients were stratified into four responder profiles as illustrated in Fig. 6: Early High Responders (≥80 % relief by 6 weeks, n = 38), Early Responders (50–79 % by 6 weeks, n = 27), Short-term Responders (50–79 % by 12 weeks, n = 6), and Non responders (<50 % by 12 weeks, n = 15). Stacked bar annotations indicated that 44 % of patients exceeded the ≥80 % threshold and 31 % exceeded 50 % relief but fell below 80 % by week 6. By week 12 (short-term), 82.6 % of patients were responders (≥50 % pain relief) and 17.4 % were non-responders (<50 % relief). This distribution reinforces the high prevalence of meaningful early to short-term response to BVNA in this population. Stacked bar plot showing responder profiles after BVNA (N=86). Responders are categorized as Early High Responders (≥80 % relief by 6 weeks), Early Responders (50–79 % relief by 6 weeks), Short-term Responders(50–79 % relief by 12 weeks), and Nonresponders (<50 % relief by 12 weeks). Bars are color-coded and labeled by absolute patient count and response level. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Change in functional disability distribution Functional outcomes improved markedly following BVNA, as illustrated in Fig. 7. At baseline, the majority of patients were categorized as crippled (43 %) or severely disabled (29 %), with only 5 % classified as having moderate disability and none with minimal disability. By 12 weeks, a substantial shift toward lower disability levels was observed, with 59 patients (≈60 %) transitioning to moderate disability and 13 (13 %) achieving minimal disability. This trend persisted through 24 weeks, with 54 patients remaining in the moderate disability category and 16 (16 %) maintaining minimal disability status. Concurrently, the proportions of patients classified as crippled or bed-bound decreased sharply. Collectively, these changes demonstrate a pronounced and sustained improvement in functional capacity following BVNA, consistent with the observed reductions in pain intensity and high overall responder rates. Change in Functional Disability Category Distribution Over Time. The heatmap illustrates shifts in Oswestry Disability Index (ODI) categories from baseline through 12 and 24 weeks following BVNA. Each cell represents the number of patients within a given disability category at each follow-up. A marked redistribution was observed with improvements sustained through 24 weeks, underscoring the durability of functional recovery following BVNA. Change in utilization of adjunctive interventions Spine-related intervention utilization declined markedly in the 6 months following BVNA (Table 6). Overall injection frequency decreased from 86.0 % pre-procedure to 22.1 % post-procedure (p < 0.0001). Significant reductions were observed across injection types, including epidural (36.0 % → 10.5 %, p = 0.001), facet joint intra-articular (32.6 % → 8.1 %, p = 0.001), medial branch block (26.7 % → 7.0 %, p = 0.002), and sacroiliac joint injections (17.4 % → 3.5 %, p = 0.005). Peripheral nerve stimulator use remained stable (8.1 % → 5.8 %, p = 0.687). Collectively, these findings indicate a substantial post-BVNA reduction in reliance on repeat interventional pain procedures, consistent with sustained analgesic and functional benefit. Table 6Utilization of Adjunctive Interventions 6-Months Before and After Basivertebral Nerve Ablation (BVNA). This table compares the frequency of spine-related injections and peripheral nerve stimulation procedures during the 6-month periods preceding and following BVNA, with p values (McNemar) and 95 % CIs for changes in utilization.Table 6Treatment6 months pre-BVNA, n (%)6 months post-BVNA, n (%)p-valueDifference in proportions (95 % CI)Injections (any)74 (86.0 %)19 (22.1 %)<0.0001−0.64 (−0.75, −0.52)Epidural31 (36.0 %)9 (10.5 %)0.001−0.26 (−0.39, −0.14)Facet joint intra-articular28 (32.6 %)7 (8.1 %)0.001−0.24 (−0.36, −0.12)Medial branch block23 (26.7 %)6 (7.0 %)0.002−0.20 (−0.32, −0.09)Sacroiliac joint15 (17.4 %)3 (3.5 %)0.005−0.14 (−0.25, −0.05)Peripheral Nerve Stimulator7 (8.1 %)5 (5.8 %)0.687−0.02 (−0.10, 0.05) Utilization of Adjunctive Interventions 6-Months Before and After Basivertebral Nerve Ablation (BVNA). This table compares the frequency of spine-related injections and peripheral nerve stimulation procedures during the 6-month periods preceding and following BVNA, with p values (McNemar) and 95 % CIs for changes in utilization. Discussion In this prospective cohort of 86 patients undergoing basivertebral nerve ablation (BVNA), the majority experienced rapid, clinically meaningful, and durable improvements in pain and function. By 12 weeks, 74 % achieved ≥50 % pain relief, a rate that remained stable at 73 % through 24 weeks. Importantly, nearly one-fifth of patients reported complete (100 %) pain resolution at both 12 and 24 weeks, while the largest subgroup (26–27 %) demonstrated 75–99 % improvement, concordant with prior reports [7,13,19]. These findings indicate a strong and sustained analgesic effect following BVNA, with results consistent across multiple analytic approaches and time points. Weekly follow up allowed this study to addresses a clinically meaningful question for patients, providers, and policymakers alike: how quickly does pain relief emerge following BVNA, and is it durable? Early response trajectory and predictive value Most patients reported meaningful pain relief within the first month of treatment. Cumulative responder analyses showed that 34 % achieved ≥50 % relief by Week 1 and 76 % by Week 3, with the curve plateauing around Week 8, suggesting early stabilization of benefit. The likelihood ratio analysis further demonstrated that early responders (≥50 % by Week 3) were 6.5 times more likely to maintain relief at 12 weeks, with peak predictive value between Weeks 4–6 (LR+ range: 7.1–9.0). Low negative likelihood ratios (≤0.13) during this window highlight the potential clinical value of early nonresponse as an indicator for reassessment. Together, the results underscore an objective data-driven framework for anticipating patient trajectories and guiding follow-up decisions after BVNA. Magnitude and depth of pain relief Beyond responder thresholds, the distribution of pain relief showed a progressive rightward shift toward higher levels of benefit. By Week 12, 21 % of patients reported complete pain resolution and most fell within the 91–100 % relief range. This pattern reinforces the internal consistency of the analgesic response and complements prior real-world and trial data reporting 64–72 % responder rates at 6–24 months, as well as higher response rates observed in early studies (e.g., De Vivo et al., 2021; Fischchenko et al., 2021). Functional and disability improvements Functional outcomes mirrored these pain reductions. Mean Oswestry Disability Index (ODI) scores improved from 66.5 to 32.3 at 12 weeks and remained stable at 24 weeks, while mean pain scores decreased from 8.3 to 3.0 over the same period (both p < 0.0001). The majority of patients achieved ≥15-point ODI improvement (≈90 %), and 70 % met the more stringent ≥30-point threshold, reflecting substantial functional recovery. Consistent with these results, 91.9 % of participants reported a PGIC ≥6, indicating a high level of perceived benefit and satisfaction. Responder phenotypes When stratified by timing and magnitude of improvement, 62 % of patients met criteria for early responders (≥50 % relief by 6 weeks), with nearly half of these classified as early high responders (≥80 % relief). Only 22 % of patients were nonresponders (<50 % by 12 weeks). This heterogeneity highlights clinically relevant subgroups that may inform individualized follow-up intensity and adjunctive care planning. Shift in functional disability categories At baseline, the majority of patients were categorized as crippled (43 %) or severely disabled (29 %). By 12 weeks, 72 patients (≈73 %) transitioned to moderate or minimal disability, and this improvement was sustained at 24 weeks. These categorical shifts underscore meaningful recovery in functional independence, paralleling pain relief trends and reinforcing that BVNA benefits extend beyond symptom reduction to tangible gains in daily function. Reduced reliance on adjunctive interventions A notable finding was the marked decline in spine-related procedural utilization post-BVNA. The overall rate of injection-based interventions fell from 86 % to 22 %, with significant reductions across all major categories—including epidural, facet, medial branch, and sacroiliac injections (all p ≤ 0.005). Peripheral nerve stimulator use remained stable. This decrease in adjunctive interventions suggests both clinical and potential cost-saving implications, reflecting durable benefit and reduced procedural dependency following BVNA. Context within existing literature and clinical implications under regulatory restrictions The magnitude and durability of improvement observed here are consistent with prior randomized controlled trials and long-term follow-ups demonstrating sustained benefit through five years [13]. Fischgrund et al. reported 66 % of patients with >50 % pain reduction and 34 % achieving complete pain resolution at 5 years, paralleling the high response and remission rates in our cohort. The alignment of these results across independent settings reinforces the reproducibility and real-world effectiveness of BVNA. Our findings also have practical implications in the context of current Medicare guidelines, which restrict BVNA treatment to a single vertebral segment (two levels) even when Modic changes extend across multiple levels. The observed negative likelihood ratios (LR− = 0.00 at 3 weeks and 0.54 at 12 weeks) indicate that lack of ≥50 % pain relief by 3–4 weeks strongly predicts nonresponse at 24 weeks. These data suggest that early (3–4 week) treatment nonresponse may serve as a clinically useful indicator for reconsidering care trajectory and, when permissible, evaluating additional affected vertebral levels. Such early reassessment may be particularly relevant under payer restrictions to optimize both timing and patient selection for subsequent BVNA interventions. Adverse events Observed adverse events to date in the study cohort included: one individual with an undiagnosed bleeding disorder and aberrant lumbosacral vascular anatomy who experienced significant hemorrhage requiring intensive care unit admission. Diagnostic evaluation revealed a previously unrecognized Factor X deficiency. The patient was ultimately safely discharged home after 3 days having received appropriate replacement therapy with factor concentrates. Three patients reported transient limb dysesthesias and leg weakness, all resolving within one week of oral corticosteroids. Two patients developed worsening axial pain post-procedure lasting approximately six weeks. These complications are consistent with the incidence of adverse events reported in prior clinical trials and real-world studies [7,[10], [11], [12], [13], [14], [15],[20], [21], [22], [23], [24]]. Nonetheless, clinicians should remain vigilant for underlying bleeding disorders and anatomic variations in lumbosacral vascular structures when planning or performing BVNA, as these factors may increase procedural risk. Limitations and future directions This study has some limitations. First, while prospective and single-center, the study lacked a control arm and follow up was limited to 24 weeks, which restricts causal inference regarding BVNA-specific effects. Second, although patients were followed longitudinally over a 24-week follow-up period, external validation in larger, multicenter, or comparative trials is warranted. Third, while our responder rates may appear higher than those reported in some randomized clinical trials and systematic reviews (e.g., Fischgrund et al., 2018; Smuck et al., 2021; McCormick et al., 2025), they are consistent with outcomes observed in several real-world and early prospective studies (De Vivo et al., 2021: 96.5 % responders; Fishchenko et al., 2021: 84.2 % ≥ 50 % pain reduction) [7,11,13,20,21]. This variability underscores an important methodological point—that responder rates in BVNA research are highly dependent on the analytic approach, assessment threshold, and timing of evaluation. When interpreted in that context, our findings fall within the expected range for BVNA in appropriately selected vertebrogenic pain populations. Fourth, psychosocial and biomechanical factors were not assessed, which may influence interindividual variability in response. Our results add to this literature by providing granular, week-by-week data on the trajectory of pain relief, an area previously unexplored in real-world settings [7,[21], [22], [23], [24]]. Importantly, the use of both 7- and 15-min ablation protocols reflects contemporary practice aligned with updated manufacturer guidance, acknowledging that improved probe targeting in newer generations of the Intracept® system allows effective lesioning with shorter ablation times and smaller lesion radii (1 mm difference) [7,22]. Future work should incorporate longer-term follow-up, PROMIS-based function metrics, and wearable-derived activity measures to inform comprehensive evaluation of BVNA outcomes [25]. Finally, although exploratory analyses revealed no differences in outcomes between 7- and 15-min ablation durations, this study was not powered to detect effects related to lesion size or ablation parameters. Adequately powered studies are warranted to further examine whether lesion size or duration meaningfully influences treatment response. Future analyses from this ongoing perspective cohort will also further examine demographic, clinical, and imaging predictors of BVNA treatment success—including pain duration, BMI, Modic type, and lesion parameters—to identify patient-level factors associated with early versus sustained response trajectories. Conclusion In summary, this prospective single-center observational cohort showed that BVNA resulted in early, substantial, and durable improvements in pain and function among patients with vertebrogenic low back pain. Most patients experienced meaningful relief within 3–6 weeks, with functional recovery and reduced healthcare utilization persisting through 24 weeks. These findings support BVNA as a robust, real-world therapeutic option and highlight the value of early pain trajectory monitoring for optimizing post-procedural management. Funding This study was supported in part by Intramural funding from the Yale School of Medicine, Department of Orthopedics & Rehabilitation. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Charles Odonkor reports a relationship with International Pain and Spine Intervention Society that includes research committee membership, and travel reimbursement. Charles Odonkor reports a relationship with Boston Scientific that includes consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements The authors would like to thank Christina Smith, RN, and Vishali Chauhan, research coordinators for assistance with data collection, chart review and organization. References